176 related articles for article (PubMed ID: 21115573)
21. PCSK9 and LDL cholesterol: unravelling the target to design the bullet.
Costet P; Krempf M; Cariou B
Trends Biochem Sci; 2008 Sep; 33(9):426-34. PubMed ID: 18672372
[TBL] [Abstract][Full Text] [Related]
22. Lipoprotein(a) in Familial Hypercholesterolemia With Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Gain-of-Function Mutations.
Tada H; Kawashiri MA; Yoshida T; Teramoto R; Nohara A; Konno T; Inazu A; Mabuchi H; Yamagishi M; Hayashi K
Circ J; 2016; 80(2):512-8. PubMed ID: 26632531
[TBL] [Abstract][Full Text] [Related]
23. Molecular characterization of familial hypercholesterolemia in Spain.
Palacios L; Grandoso L; Cuevas N; Olano-Martín E; Martinez A; Tejedor D; Stef M
Atherosclerosis; 2012 Mar; 221(1):137-42. PubMed ID: 22244043
[TBL] [Abstract][Full Text] [Related]
24. Identification and functional characterization of LDLR mutations in familial hypercholesterolemia patients from Southern Italy.
Romano M; Di Taranto MD; D'Agostino MN; Marotta G; Gentile M; Abate G; Mirabelli P; Di Noto R; Del Vecchio L; Rubba P; Fortunato G
Atherosclerosis; 2010 Jun; 210(2):493-6. PubMed ID: 20045108
[TBL] [Abstract][Full Text] [Related]
25. Functional characterization of mutant genes associated with autosomal dominant familial hypercholesterolemia: integration and evolution of genetic diagnosis.
Di Taranto MD; D'Agostino MN; Fortunato G
Nutr Metab Cardiovasc Dis; 2015 Nov; 25(11):979-87. PubMed ID: 26165249
[TBL] [Abstract][Full Text] [Related]
26. Advances in genetics show the need for extending screening strategies for autosomal dominant hypercholesterolaemia.
Motazacker MM; Pirruccello J; Huijgen R; Do R; Gabriel S; Peter J; Kuivenhoven JA; Defesche JC; Kastelein JJ; Hovingh GK; Zelcer N; Kathiresan S; Fouchier SW
Eur Heart J; 2012 Jun; 33(11):1360-6. PubMed ID: 22408029
[TBL] [Abstract][Full Text] [Related]
27. Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk.
Humphries SE; Whittall RA; Hubbart CS; Maplebeck S; Cooper JA; Soutar AK; Naoumova R; Thompson GR; Seed M; Durrington PN; Miller JP; Betteridge DJ; Neil HA;
J Med Genet; 2006 Dec; 43(12):943-9. PubMed ID: 17142622
[TBL] [Abstract][Full Text] [Related]
28. APOE p.Leu167del mutation in familial hypercholesterolemia.
Awan Z; Choi HY; Stitziel N; Ruel I; Bamimore MA; Husa R; Gagnon MH; Wang RH; Peloso GM; Hegele RA; Seidah NG; Kathiresan S; Genest J
Atherosclerosis; 2013 Dec; 231(2):218-22. PubMed ID: 24267230
[TBL] [Abstract][Full Text] [Related]
29. Reduced penetrance of autosomal dominant hypercholesterolemia in a high percentage of families: importance of genetic testing in the entire family.
Garcia-Garcia AB; Ivorra C; Martinez-Hervas S; Blesa S; Fuentes MJ; Puig O; Martín-de-Llano JJ; Carmena R; Real JT; Chaves FJ
Atherosclerosis; 2011 Oct; 218(2):423-30. PubMed ID: 21868016
[TBL] [Abstract][Full Text] [Related]
30. The genetic spectrum of familial hypercholesterolemia in Pakistan.
Ahmed W; Whittall R; Riaz M; Ajmal M; Sadeque A; Ayub H; Qamar R; Humphries SE
Clin Chim Acta; 2013 Jun; 421():219-25. PubMed ID: 23535506
[TBL] [Abstract][Full Text] [Related]
31. Spectrum of mutations and phenotypic expression in patients with autosomal dominant hypercholesterolemia identified in Italy.
Bertolini S; Pisciotta L; Rabacchi C; Cefalù AB; Noto D; Fasano T; Signori A; Fresa R; Averna M; Calandra S
Atherosclerosis; 2013 Apr; 227(2):342-8. PubMed ID: 23375686
[TBL] [Abstract][Full Text] [Related]
32. Low-density lipoprotein receptor activity in Epstein-Barr virus-transformed lymphocytes from heterozygotes for the D374Y mutation in the PCSK9 gene.
Holla ØL; Cameron J; Berge KE; Kulseth MA; Ranheim T; Leren TP
Scand J Clin Lab Invest; 2006; 66(4):317-28. PubMed ID: 16777760
[TBL] [Abstract][Full Text] [Related]
33. Genetic heterogeneity of autosomal dominant hypercholesterolemia in Mexico.
Robles-Osorio L; Huerta-Zepeda A; Ordóñez ML; Canizales-Quinteros S; Díaz-Villaseñor A; Gutiérrez-Aguilar R; Riba L; Huertas-Vázquez A; Rodríguez-Torres M; Gómez-Díaz RA; Salinas S; Ongay-Larios L; Codiz-Huerta G; Mora-Cabrera M; Mehta R; Gómez Pérez FJ; Rull JA; Rabès JP; Tusié-Luna MT; Durán-Vargas S; Aguilar-Salinas CA
Arch Med Res; 2006 Jan; 37(1):102-8. PubMed ID: 16314194
[TBL] [Abstract][Full Text] [Related]
34. Urine-sample-derived human induced pluripotent stem cells as a model to study PCSK9-mediated autosomal dominant hypercholesterolemia.
Si-Tayeb K; Idriss S; Champon B; Caillaud A; Pichelin M; Arnaud L; Lemarchand P; Le May C; Zibara K; Cariou B
Dis Model Mech; 2016 Jan; 9(1):81-90. PubMed ID: 26586530
[TBL] [Abstract][Full Text] [Related]
35. Loss-of-function mutation R46L in the PCSK9 gene has little impact on the levels of total serum cholesterol in familial hypercholesterolemia heterozygotes.
Strøm TB; Holla ØL; Cameron J; Berge KE; Leren TP
Clin Chim Acta; 2010 Feb; 411(3-4):229-33. PubMed ID: 19917273
[TBL] [Abstract][Full Text] [Related]
36. LDLR gene synonymous mutation c.1813C>T results in mRNA splicing variation in a kindred with familial hypercholesterolaemia.
Ho CK; Musa FR; Bell C; Walker SW
Ann Clin Biochem; 2015 Nov; 52(Pt 6):680-4. PubMed ID: 25624525
[TBL] [Abstract][Full Text] [Related]
37. Proprotein convertase subtilisin/kexin 9 V4I variant with LDLR mutations modifies the phenotype of familial hypercholesterolemia.
Ohta N; Hori M; Takahashi A; Ogura M; Makino H; Tamanaha T; Fujiyama H; Miyamoto Y; Harada-Shiba M
J Clin Lipidol; 2016; 10(3):547-555.e5. PubMed ID: 27206942
[TBL] [Abstract][Full Text] [Related]
38. Proprotein convertase subtilisin kexin 9: the third locus implicated in autosomal dominant hypercholesterolemia.
Maxwell KN; Breslow JL
Curr Opin Lipidol; 2005 Apr; 16(2):167-72. PubMed ID: 15767856
[TBL] [Abstract][Full Text] [Related]
39. No genetic linkage or molecular evidence for involvement of the PCSK9, ARH or CYP7A1 genes in the Familial Hypercholesterolemia phenotype in a sample of Danish families without pathogenic mutations in the LDL receptor and apoB genes.
Damgaard D; Jensen JM; Larsen ML; Soerensen VR; Jensen HK; Gregersen N; Jensen LG; Faergeman O
Atherosclerosis; 2004 Dec; 177(2):415-22. PubMed ID: 15530918
[TBL] [Abstract][Full Text] [Related]
40. LDLR and ApoB are major genetic causes of autosomal dominant hypercholesterolemia in a Taiwanese population.
Yang KC; Su YN; Shew JY; Yang KY; Tseng WK; Wu CC; Lee YT
J Formos Med Assoc; 2007 Oct; 106(10):799-807. PubMed ID: 17964958
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
